Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API

Health Systems, Economic Evaluations, Quality of Life

58 ta ish

  1. Identification of Bioactive Compounds of the Endophytic Fungus <i>Aspergillus egypticus</i>-HT166S Inhibiting the Activity of Pancreatic α-Amylase

    D. M. Ruzieva, T.G. Gulyamova, Saodat Nasmetova +2

    MaqolaComputational Drug Discovery MethodsTurkish Journal of Pharmaceutical Sciences20210 iqtibos
    ABI

  2. Pharmacoeconomics and the Patients’ Compliance as an Essential part of Successful therapy of iron Deficiency Anemia.

    Khodjieva Gulirano Sayfullaevna

    MaqolaHealth Systems, Economic Evaluations, Quality of LifeIndonesian Journal of Innovation Studies20220 iqtibos
    ABI

  3. POS-592 COMPARATIVE ANALYSIS OF THE CAUSES OF DEATH IN DIALYSIS PATIENTS WITH AND WITHOUT CARDIOVASCULAR DISEASES

    Olimkhon Sharapov, Botir Daminov, Sherzod Abdullaev

    MaqolaBlood Pressure and Hypertension StudiesKidney International Reports20220 iqtibos
    ABI

  4. Case in clinical practice: Modern intensive care in the treatment of post-resuscitation complications caused by cardiac arrhythmias

    Khayitov Dilshod Khayotovich, Boltayev Elmurod Bekmurodugli

    MaqolaCardiac electrophysiology and arrhythmiasACADEMICIA An International Multidisciplinary Research Journal20220 iqtibos
    ABI

  5. What Is the Scope of Fair and Equitable Treatment (FET) Standard, What Is the Effect or Its Alleged Breadth?

    Saidyakhyo Usmankhodjaev

    MaqolaHealth Systems, Economic Evaluations, Quality of LifeSSRN Electronic Journal20230 iqtibos
    ABI

  6. The reported impact of non-communicable disease investment cases in 13 countries

    Giuseppe Troisi, Roy Small, Roman Chestnov +36

    MaqolaGlobal Public Health Policies and EpidemiologyBMJ Global Health20240 iqtibos
    ABI

  7. Bradford Assay v1

    Jailyn Izu

    PreprintHealth Systems, Economic Evaluations, Quality of Life20240 iqtibos
    ABI

  8. Advancements in risk stratification and management strategies in primary cardiovascular prevention

    Fotios Barkas, Yusuf Ziya Şener, Pelin Golforoush +25

    Sharh maqolaLipoproteins and Cardiovascular HealthAtherosclerosis20240 iqtibos
    ABI

  9. Drug-drug interactions in clinical practice: a literature review and SWOT analysis

    Valeriya O. Barysheva, О. S. Golikova, В. Г. Кудрина +1

    Sharh maqolaPharmaceutical Practices and Patient OutcomesMedical Technologies Assessment and Choice20240 iqtibos
    ABI

  10. Defining Health Management: A Conceptual Foundation for Excellence Through Efficiency, Sustainability and Equity

    George Valiotis, Sandra C. Buttiġieġ, Americo Cicchetti +12

    MaqolaHealth Systems, Economic Evaluations, Quality of LifeThe International Journal of Health Planning and Management20250 iqtibos
    ABI

  11. Determining Indicators of Medical Care Quality in Private Health Institutions

    G. A. Kabilova

    MaqolaHealth Systems, Economic Evaluations, Quality of LifeAcademia Open20250 iqtibos
    ABI

  12. Optimizing Healthcare Quality Through ISO 9001:2015 and ISO 7101:2023 Standards

    Komilov Bekzodbek Maxmudjon Ugli

    MaqolaQuality and Supply ManagementAcademia Open20250 iqtibos
    ABI

  13. Dual‐Criterion Approach Incorporating Historical Information to Seek Accelerated Approval With Application in Time‐to‐Event Group Sequential Trials

    Marco Ratta, Gaëlle Saint‐Hilary, Valentine Barboux +3

    MaqolaAdvanced Causal Inference TechniquesStatistics in Medicine20260 iqtibos
    ABI

  14. Rare diseases as a global priority: the CIS Orphan Forum and the path toward collaboration with BRICS

    Nuriya Z. Musina, Ahmed Al Saidi, Ayman W. El-Hattab +27

    MaqolaGenomics and Rare DiseasesThe BRICS Health Journal20260 iqtibos
    ABI

  15. Advancing global health economics and policy of palliative and end-of-life care: insights from Ireland, Norway, Finland, Argentina, and India

    Claudia Fischer, Gudrun Waaler Bjørnelv, Rui Dang +2

    MaqolaGlobal Health Care IssuesAnnals of Palliative Medicine20260 iqtibos
    ABI

  16. valuation

    Yoshimitsu Katayama

    PreprintHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  17. valuation framework

    Yoshimitsu Katayama

    PreprintHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  18. valuation framework

    Yoshimitsu Katayama

    PreprintHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  19. valuation framework

    Yoshimitsu Katayama

    PreprintHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  20. valuation framework

    Yoshimitsu Katayama

    PreprintHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  21. valuation framework

    Yoshimitsu Katayama

    PreprintHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  22. theykch valuation framework

    Yoshimitsu Katayama

    PreprintHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  23. valuation framework

    Yoshimitsu Katayama

    PreprintHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  24. valuation

    Yoshimitsu Katayama

    PreprintHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  25. valuation framework

    Yoshimitsu Katayama

    PreprintHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI